Hepatocellular proliferation and hepatocarcinogen bioactivation in mice with diet-induced fatty liver and obesity

Experimental and Toxicologic Pathology

Volumn 65, Issue 4, 2013, Pages 451-456

  Iatropoulos, M J ^a   Duan, J D ^a   Jeffrey, A M ^a   Leach, M W ^b   Hayes, A N ^b   Stedman, N L ^b   Williams, G M ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b PFIZER INC   (United States)

Author keywords

2 Acetylaminofluorene; Diet induced obesity; DNA adduct formation; Fatty liver hepatic steatosis; Hepatocellular proliferation

Indexed keywords

CYCLINE; DNA; N (2 FLUORENYL)ACETAMIDE; TRIACYLGLYCEROL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN DETECTION; ARTICLE; BODY WEIGHT; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; DNA ADDUCT; FATTY LIVER; IMMUNOHISTOCHEMISTRY; LIVER CARCINOGENESIS; LIVER CELL; LIVER WEIGHT; MALE; MOUSE; NONHUMAN; OBESITY; REFERENCE VALUE;

MUS;

EID: 84875878294     PISSN: 09402993     EISSN: 16181433     Source Type: Journal    
DOI: 10.1016/j.etp.2012.01.003     Document Type: Article

References (52)

1. Bernstein L.M. Role of endocrine-genotoxic switchings in cancer and other human diseases: basic triad. Adv Exp Med Biol 2008, 630:35-51.
2. Bugianesi E. Non-alcoholic steatohepatitis and cancer. Clin Liver Dis 2007, 11:191-207.
3. Chávez-Tapia N.C., Méndez-Sánchez N., Uribe M. Role of nonalcoholic fatty liver disease in hepatocellular carcinoma. Ann Hepatol 2009, 8:S34-S39.
4. Coulouarn C., Gomez-Quiroz L.E., Lee J.S., Kaposi-Novak P., Conner E.A., Goldina T.A., et al. Oncongene-specific gene expression signatures at preneoplastic state in mice define distinct mechanisms of hepatocarcinogenesis. Hepatology 2006, 44:1003-1011.
5. Diehl A.M. Lessons from animal models. Hepatol Res 2005, 33:137-144.
6. Donato F., Gelatti U., Limina R.M., Fattovich G. Southern Europe as an example of interaction between various environmental factors: a systematic review of the epidemiologic evidence. Oncogene 2006, 25:3756-3770.
7. Dunnett C.W. A multiple comparison procedure for comparing several treatments with a control. J Am Stat Assoc 1955, 50:1096-1121.
8. Feldstein A.E., Canbay A., Guicciardi M.E., Higuchi H., Bronk S.F., Gores G.J. Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice. J Hepatol 2003, 39:978-983.
9. Fossati P., Prencipe L. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clin Chem 1982, 28(10):2077-2080.
10. Frith C.H., Highman B., Burger G., Sheldon W.D. Spontaneous lesions in virgin and retired breeder BALB/c and C57BL/6 mice. Lab Anim Sci 1983, 33:273-286.
11. Gholam P.M., Flancbaum L., Machan J.T., Charney D.A., Kotler D.P. Nonalcoholic fatty liver disease in severely obese subjects. Am J Gastroenterol 2007, 102:399-408.
12. 32P-postlabeling analysis of non-radioactive aromatic carcinogen - DNA adducts. Carcinogenesis 1982, 3:1081-1092.
13. Hill-Baskin A.E., Markiewski M.M., Buchner D.A., Shao H., DeSantis D., Hsiao G., et al. Diet-inducted hepatocellular carcinoma in genetically predisposed mice. Hum Mol Genet 2009, 18(16):2975-2988.
14. Hjartaker A., Langseth H., Weiderpass E. Obesity and diabetes epidemics: cancer repercussions. Adv Exp Med Biol 2008, 630:72-93.
15. Huang H.L., Lin W.Y., Lee L.T., Wang H.H., Lee W.J., Huang K.C. Metabolic syndrome is related to nonalcoholic steatohepatitis in severely obese subjects. Obes Surg 2007, 17:1457-1463.
16. Iatropoulos M.J., Williams G.M. Proliferation markers. Exp Toxicol Pathol 1996, 48:175-181.
17. Jeffrey A.M., Luo FlQ, Amin S., Krzeminski J., Zech K., Williams G.M. Lack of DNA binding on the rat nasal mucosa and other tissues of the nasal toxicants roflumilast, a phosphodiesterase 4 inhibitor, and a metabolite, 4-amino-3,5-dichloropyridine, in contrast to the nasal carcinogen 2,6-dimethylaniline. Drug Chem Toxicol 2002, 25:93-107.
18. Jou J., Choi S.S., Diehl A.M. Mechanisms of disease progression in nonalcoholic fatty liver disease. Semin Liver Dis 2008, 28:370-379.
19. Kershaw E.E., Flier J.S. Adipose tissue as an endocrine organ. J Clin Endocrinol Metabol 2004, 89:2548-2556.
20. Lee J.S., Grisham J.W., Thorgeirsson S.S. Comparative functional genomics for identifying model of human cancer. Carcinogenesis 2005, 26:1013-1020.
21. Leong C.O., Gaskell M., Martin E.A., Heydon R.T., Farmer P.B., Bibby M.C., et al. Antitumour 2-(4-aminophenyl)benzothiasoles generate DNA adducts in sensitive tumour cells in vitro and in vivo. Br J Cancer 2003, 88:470-477.
22. Luedde T., Beraza N., Kotsikoris V., van Loo G., Nenci A., De Vos R., et al. Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell 2007, 11:119-132.
23. Mathur A., Marine M., Lu D., Swartz-Basile D.A., Saxena R., Zyromski N.J. Nonalcoholic fatty pancreas disease. HPB 2007, 9:312-318.
24. Neuschwander-Tetri B.A. Nonalcoholic steatohepatitis and the metabolic syndrome. Am J Med Sci 2005, 330:326-335.
25. Nishikawa S., Doi K., Nakayama H., Uetsuka K. The effect of fasting on hepatic lipid accumulation and transcriptional regulation of lipid metabolism differs between C57BL/6J and BALB/cA mice fed a high-fat diet. Toxicol Pathol 2008, 36:850-857.
26. Otu H.H., Naxerova K., Ho K., Nesbitt N., Libermann T.A., Karp S.J. Restoration of liver mass after injury requires proliferative and not embryonic transcriptional patterns. J Biol Chem 2007, 282:11197-11204.
27. Pang R., Tse E., Poon R.T. Molecular pathways in hepatocellular carcinoma. Cancer Lett 2006, 240:157-169.
28. Parkin D.M. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006, 118:3030-3044.
29. Phillips D.H., Castegnaro M. Standardization and validation of DNA adduct postlabeling methods: report of interlaboratory trials and production of recommended protocols. Mutagenesis 1999, 14:301-315.
30. Qian Y., Fan J.G. Obesity, fatty liver and liver cancer. Hepatobiliary Pancreat Dis Int 2005, 4:173-177.
31. 32P-postlabeling test for structurally diverse DNA adducts. Carcinogenesis 1986, 7:1543-1551.
32. Scherer P.E. Adipose tissue: from lipid storage compartment to endocrine organ. Diabetes 2006, 55:1537-1545.
33. Schmeiser HH, Bieler C., Wiessler M, Fried M, Erdinger L. Identification of specific DNA-adduct patterns in organic chemical structures in outdoor air [in German]; 1999. Available at: [accessed 15.06.08]. http://bwplus.fzk.de/berichte/ZberL96011.pdf.
34. Schütte K., Bornschein J., Malfertheiner P. Hepatocellular carcinoma-epidemiological trends and risk factors. Digest Dis 2009, 27:80-92.
35. Stedman N.L., Hayes A.N., Leach M.W. Predisposition of diet-induced obese C57BL/6J mice to liver and lung neoplasms. Vet Pathol 2009, 46(5):1060.
36. Surwit R.S., Seldin M.F., Kuhn C.M., Secor C., Feinglos M.N. Diet-induced obesity and diabetes in C57BL/6J and C57BL/KsJ mice. Mouse Genome 1994, 92:523-525.
37. Surwit R.S., Feinglos M.N., Rodin J., Sutherland A., Petro A.E., Opara E.C., et al. Differential effects of fat and sucrose on the development of obesity and diabetes in C57BL/6J and A/J mice. Metabolism 1995, 44:645-651.
38. Surwit R.S., Kuhn C.M., Cochrane C., McCubbin J.A., Feinglos M.N. Diet-induced type II diabetes in C57BL/6J mice. Diabetes 1998, 37:1163-1167.
39. Systat Software Inc.; 2004.
40. Tanaka N., Moriya K., Kiyosawa K., Koike K., Gonzalez F.J., Aoyama T. PPAR alpha activation is essential for HCV core protein induced hepatic steatosis and hepatocellular carcinoma in mice. J Clin Invest 2008, 188:683-694.
41. Thorgeirsson S.S., Grisham J.W. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002, 31:339-346.
42. Tward A.D., Jones K.D., Yant S., Cheung S.T., Fan S.T., Chen X., et al. Distinct pathways of genomic progression to benign and malignant tumors of the liver. Proc Natl Acad Sci USA 2007, 104:14771-14776.
43. Verna L., Whysner J., Williams G.M. 2-Acetylaminofluorene mechanistic data and risk assessment: DNA reactivity, enhanced cell proliferation and tumor initiation. Pharmacol Ther 1996, 71:83-105.
44. Wang Y., Ausman L.M., Greenberg A.S., Russell R.M., Wang X.D. Nonalcoholic steatohepatitis induced by high-fat diet promotes diethylnitrosamine initiated early hepatocarcinogenesis in rats. Int J Cancer 2009, 124(3):540-546.
45. Website, [accessed March 2011]. http://jaxmice.jax.org/diomice/diets.html.
46. Williams G.M. Chemicals with carcinogenic activity in rodent liver. Comprehensive Toxicology 2010, vol. 9:221-250. Academic Press, Oxford.
47. Williams G.M., Iatropoulos M.J. Alteration of liver cell function and proliferation: differentiation between adaptation and toxicity. Toxicol Pathol 2002, 30:41-53.
48. Williams G.M., Iatropoulos M.J., Wang C.X., Jeffrey A.M., Thompson S., Pittman B., et al. Non-linearities in 2-acetylaminofluorene exposure-responses for genotoxic and epigenetic effects leading to initiation of carcinogenesis in rat liver. Toxicol Sci 1998, 45:152-161.
49. Williams G.M., Iatropoulos M.J., Jeffrey A.M. Thresholds for the effects of 2-acetylaminofluorene in rat liver. Toxicol Pathol 2004, 32(Suppl. 2):85-91.
50. Williams G.M., Iatropoulos M.J., Jeffrey A.M. Thresholds for DNA-reactive (genotoxic) organic carcinogens. J Toxicol Pathol 2005, 18:69-77.
51. Yanagitani A., Yamada S., Yasui S., Shinomura T., Murai R., Murawaki Y., et al. Retinoic acid receptor α dominant negative form causes steatohepatitis and liver tumors in transgenic mice. Hepatology 2004, 40:366-375.
52. Yang S., Lin H.Z., Hwang J., Chacko V.P., Diehl A.M. Hepatic hyperplasia in noncirrhotic fatty livers: is obesity-related hepatic steatosis a premalignant condition?. Cancer Res 2001, 61:5016-5023.